BTIG Believes Orthofix (NASDAQ: OFIX) Still Has Room to Grow

In a report released today, Ryan Zimmerman from BTIG maintained a Buy rating on Orthofix (NASDAQ: OFIX), with a price target of $62. The company’s shares closed yesterday at $61.02, close to its 52-week high of $61.86.

According to TipRanks.com, Zimmerman is a 5-star analyst with an average return of 40.3% and a 69.2% success rate. Zimmerman covers the Healthcare sector, focusing on stocks such as Integra Lifesciences, OrthoPediatrics Corp, and SeaSpine Holdings.

Orthofix has an analyst consensus of Strong Buy, with a price target consensus of $65.67.

Find more picks by Best Performing Analysts >>

Orthofix’s market cap is currently $1.12B and has a P/E ratio of 179.47. The company has a book value ratio of 3.7604.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Orthofix International NV engages in the research, development, and market of orthopedic solutions. It operates through the following business segments: BioStim, Biologics, Extremity Fixation, and Spine Fixation.